Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Ocul Immunol Inflamm. 2018 Feb 16;27(4):686–692. doi: 10.1080/09273948.2018.1424341

Table 3:

Proportion of Patients with Juvenile Idiopathic Arthritis Associated Uveitis Achieving Corticosteroid-sparing Control of Inflammation

Proportion achieving corticosteroid-sparing control
Total % IMT alone % IMT in combination %
 Methotrexate 33/42 79 19/25 76 14/17 82
 Mycophenolate mofetil 4/7 57 1/2 50 3/5 60
 Cyclosporine 5/6 83 1/1 100 4/5 80
 Adalimumab (Humira) 6/14 43 1/6 17 5/8 63
 Etanercept (Enbrel) 2/3 67 2/2 100 0/1 0
 Infliximab (Remicade) 10/11 91 3/3 100 7/8 88